Recruiting
Dato-DXd, Valemetostat
A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors
Trial #: NCT06244485
This site is for U.S. Healthcare Professionals only.
Clinical Trials
This section includes clinical trials that are “Recruiting” or “Not yet recruiting” where Daiichi Sankyo is the Sponsor or Collaborator.
Please note all information is refreshed from clinicaltrials.gov on a daily basis.
Recruiting
T-DXd
Phase 3
Gynecologic Cancers
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Trial #: NCT06989112
Recruiting
Dato-DXd
Phase 2
Phase 3
Genitourinary Cancers
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Trial #: NCT07129993
Recruiting
T-DXd
Breast Cancer
A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
Trial #: NCT06210776
Recruiting
HER3-DXd
Phase 2
Tumor-agnostic
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Trial #: NCT06172478
Recruiting
T-DXd
Tumor-agnostic
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
Trial #: NCT06973161
Recruiting
Dato-DXd
Phase 3
Breast Cancer
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
Trial #: NCT06103864
Recruiting
R-DXd
Phase 2
Tumor-agnostic
A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)
Trial #: NCT06660654
Recruiting
Valemetostat
Phase 1
Phase 2
Lung Cancer
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
Trial #: NCT06644768
Recruiting
I-DXd
Phase 2
Tumor-agnostic
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
Trial #: NCT06330064
The content contained is taken is taken directly from public registry ClinicalTrials.gov and has not been edited.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
DataSource by Daiichi Sankyo website provides U.S.
healthcare professionals with high quality, fair balanced, evidence-based medical information.
The information provided is for education purposes only and is not intended as medical advice.
Please choose an option below